Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2001

View Archived Issues

Uprima/Ixense for ED given positive opinion by CPMP

Year 2000 progress highlighted by Sepracor

Trimeris and Roche report clinical results for T-20 and T-1249

YM BioSciences and SR Pharma to codevelop cancer vaccine

Vasogen prepares Canadian trial of VAS-972 for psoriasis

Bavarian Nordic licenses vaccine technology

Chinese herbal formulation undergoes evaluation for anti-HIV, immune and cardiovascular effects

BSF-302146 may have potential for preventing restenosis following CABG surgery

F-12511: a potent ACAT inhibitor with cholesterol-lowering and antiatherosclerotic effects

Ark Therapeutics emerges as major European gene-based company

Product developments announced by Forest

Aventis and Novo Nordisk sign license agreement and end Lantus litigation

Clearance sought to begin clinical trials with INS-37217 Ophthalmic

ImaRx and Elan establish joint venture for HydroPlex drug delivery system

Sibutramine maintains significant weight loss over two years in the STORM study

Dimethaid begins mutual recognition procedure in E.U. for Pennsaid

SafeScience gains additional patent rights to GBC-590

Theratechnologies' ex vivo PDT cell therapy system enters clinical testing

Tanox updates product developments, looks ahead to 2001

Venlafaxine for the management of hot flashes in menopausal women

Selective beta2-adrenoceptor agonists and therapeutic use described by Novartis

Merck presents novel substituted piperidines as selective human MC4 receptor agonists

New MMP-inhibitory hydroxamic acid derivatives and use thereof

Thiophene integrin inhibitors designed at BioChem Pharma

Immunomodulating imidazoquinolines a focus of R&D at 3M Innovative Properties

Merck continues to investigate new chemokine receptor modulators